Participants will receive one of the two treatments for a 12‑week period and then switch to the other treatment for another 12‑week period. The design is double‑blind, meaning neither the participants nor the study staff know which inhaler is active, and a double‑dummy approach ensures each person uses two inhalers (one containing the active drug and one containing a placebo) so the experience is the same. During the study, lung function is measured with a test called FEV1, which assesses how much air can be exhaled in one second, and participants complete a short questionnaire about asthma control called ACQ‑5 and another questionnaire about quality of life called PAQLQ. Safety is monitored by recording any side effects and by checking basic blood tests and other routine examinations.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to compare how well the two medicines lower the level of LDL-C after about 12 weeks. After a screening visit, participants are randomly assigned to one of the two groups. They take the assigned tablets every day for roughly three months, with clinic visits at the start, midway, and at the end to collect blood samples and check safety.

Safety is monitored through regular physical checks, blood pressure measurements, and laboratory tests that look for any side effects. The overall aim is to see which medicine provides a greater reduction in the harmful cholesterol while being well tolerated.

The purpose of the study is to see whether olomorasib, when added to standard immunotherapy, works better and is safe for people with this type of lung cancer. The study is done in different parts. After treatment begins, participants are followed over time while taking the study medicine or placebo together with the immunotherapy medicine, and health checks are done throughout the study to watch for side effects and any changes in the cancer.

During the study, the effectiveness of tulisokibart will be monitored over a period of time. The investigation looks at how many people reach clinical remission, a state where the symptoms of the disease are significantly reduced or absent. Researchers will also observe endoscopic improvement, which refers to visible healing of the intestinal lining during a procedure where a camera is used to look inside the body, and histologic-endoscopic mucosal improvement, which means the tissue appears healthy both under a microscope and during a visual examination.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

The main purpose of this research is to determine if Xeomin is more effective than placebo in reducing the number of monthly migraine days. The study involves different doses of the medication, with participants receiving either Xeomin or placebo injections. The treatment period lasts for 6 months, during which participants will receive multiple injections.

The medication being tested, Xeomin, is a purified form of botulinum toxin that is free from complexing proteins. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of acute migraine medications. Throughout the study, participants will need to keep track of their migraine episodes and any changes in their condition.

The treatment will involve receiving regular injections of the study medications for up to 52 weeks. Mirikizumab is a type of medication called a monoclonal antibody, which works by targeting specific parts of the immune system. Tirzepatide is a medication that can help with weight management. Some participants will receive both active medications, while others will receive Mirikizumab with placebo.

The study will measure how many participants achieve two goals at the same time: improvement in their Ulcerative Colitis symptoms and a significant reduction in their body weight. The medications will be given through injections either under the skin or into a vein, depending on the specific medication being administered.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

The study will assess improvement in atopic dermatitis using several measurements, including the Validated Investigator’s Global Assessment for Atopic Dermatitis (a scoring system used by doctors to rate the severity of eczema) and the Eczema Area and Severity Index (a tool that measures the extent and severity of eczema). The research will also track changes in pruritus (itching) and skin pain using numerical rating scales where patients rate their symptoms.

During the 24-week study period, participants will receive either rocatinlimab or placebo treatment. The study is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication versus the placebo until the study is complete. This approach helps ensure that the results aren’t influenced by expectations about the treatment.

The purpose of this study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo, which is a substance with no active medication. The study will last for about 12 months, during which participants will receive regular injections and have their triglyceride levels monitored at various points to see how they change over time.

Throughout the study, participants will be closely monitored for any changes in their health and any side effects they might experience. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to see if it helps more participants reach healthier triglyceride levels. This research could lead to a new treatment option for people with severe hypertriglyceridemia, potentially improving their health and reducing the risk of complications associated with high triglyceride levels.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

The study follows a double-blind design, which means that neither the participants nor the researchers know who is receiving the active medication and who is receiving the placebo. This method is used to prevent bias in the results. During the course of the study, participants will take an oral capsule for a period of time to monitor how the medications affect their symptoms and general well-being.

Participants will take either azetukalner capsules or placebo capsules by mouth once daily for a period of time. The dose of azetukalner that will be used is 20 milligrams per day. The study will measure changes in depression symptoms over several weeks, with particular attention to how participants feel after six weeks of treatment. The study will also look at changes in the ability to feel pleasure and overall improvement in the severity of depression symptoms.

This is a randomized, double-blind, placebo-controlled study, which means that participants will be assigned by chance to receive either the active medication or placebo, and neither the participants nor the doctors will know which treatment is being given until the study is completed. The treatment period will last up to 18 months. Participants may also continue taking their regular antidepressant medication during the study.

The purpose of this study is to compare how MB11 and Opdivo work in the body, how well they control the cancer, how safe they are, and how the body’s immune system responds to them. The study wants to show that MB11 works in a similar way to Opdivo when used as the first treatment for people with melanoma that cannot be removed by surgery or has spread to other parts of the body.

During the study, participants will be randomly assigned to receive either MB11 or Opdivo. Neither the participants nor the doctors will know which medicine is being given. The treatment will be given regularly over a period of time, and participants will be monitored through regular visits where blood samples will be taken, scans will be performed to check how the cancer is responding, and any side effects will be recorded. The study will also check if the body develops an immune response to the medicine. Participants will continue to be followed for their health and survival even after the treatment period ends.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

During the study, participants will be randomly assigned to receive either the combination of XL092 and nivolumab, or sunitinib alone. The treatment may continue for up to 252 weeks (about 5 years). Regular medical examinations and scans will be performed to monitor how well the treatment is working and check for any side effects. The study will measure how long participants live without their cancer getting worse and track their overall survival time.

Participants in the study will be assigned to receive either the test medication or the comparison medication. The process involves monitoring changes in best corrected visual acuity, which refers to how clearly a person can see when wearing glasses or contact lenses. The study will observe how these treatments affect the thickness of the retina and how frequently eye treatments are required over a set period of time.

During the study, participants will receive either AVT29 or a high dose of Eylea. The medical team will monitor changes in best-corrected visual acuity, which refers to the clearest vision possible with glasses or contact lenses. Additionally, the study will look at changes in central subfield thickness, a measurement of how much the middle part of the retina has thickened due to swelling, and the presence of intraretinal fluid, which is liquid trapped inside the layers of the retina. Regular check-ups will also be performed to monitor intraocular pressure, the fluid pressure inside the eye, and other general health factors to ensure safety throughout the process.

The purpose of this study is to find out if trimodulin is effective and safe when added to standard care for treating hospitalized adult patients with community-acquired pneumonia or COVID-19 pneumonia. The study will look at whether patients who receive trimodulin do better than those who receive placebo by measuring how many patients get worse or die during the study period. Patients in the study will receive the treatment through an infusion into a vein over five days.

During the study, doctors will monitor patients for up to 91 days to see how they respond to treatment. They will check if patients need more intensive breathing support or if their condition improves, stays the same, or gets worse. The study will also measure various blood markers related to inflammation, immune system function, and blood clotting to understand how the treatment works in the body. Safety will be carefully watched by recording any unwanted effects that occur during and after the treatment period.

The main goal of this research is to determine if MT-501 is safe and effective for people with moderate to severe forms of these digestive conditions. The study is designed as a Phase 2 platform study, which means it will evaluate multiple treatment approaches for inflammatory bowel disease.

During the study, participants will go through an induction phase where they will take the study medication. Throughout this period, doctors will monitor how well the treatment works by examining the inside of the digestive tract and tracking symptoms. They will also check how the body processes the medication and look for any side effects that may occur. The study will collect information about improvements in the condition of the digestive tract lining and overall disease symptoms.

The study involves patients taking either efavaleukin alfa or placebo while continuing their current medications such as 5-aminosalicylates, corticosteroids, budesonide, beclomethasone dipropionate, or other immune system medications like azathioprine, 6-mercaptopurine, or methotrexate. The main purpose is to evaluate if efavaleukin alfa can help patients achieve clinical remission after 12 weeks of treatment.

During the study, doctors will monitor how well the treatment works by examining the digestive tract and checking for improvements in symptoms. They will also keep track of any side effects that may occur. The study is designed as a double-blind study, which means neither the patients nor the doctors know who is receiving the actual medication or the placebo during the treatment period.

The study aims to understand the long-term safety and effectiveness of efavaleukin alfa in treating people who have moderate to severe Ulcerative Colitis. This research is a continuation of a previous study, allowing researchers to gather information about how well the medication works and how safe it is when used for an extended period.

During this long-term extension study, participants will continue receiving efavaleukin alfa treatment for up to two years. Throughout this time, doctors will monitor various aspects of the participants’ health, including how well their digestive system is healing and whether their symptoms are improving. They will also keep track of any side effects that may occur during the treatment period.

The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.

The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The purpose of this research is to understand how different doses of BI 1815368 affect vision improvement in people who have varying levels of vision problems due to diabetic macular edema. The study will compare the new medication to placebo over a treatment period of 48 weeks.

During the study, participants will take tablets by mouth and have their vision regularly checked. The research team will monitor how well participants can see using standard eye tests and measure the thickness of the retina using special imaging equipment. They will also keep track of any effects that might be related to the treatment to ensure participant safety throughout the study period.